Nanoparticles for nasal vaccination

The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeabilit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced drug delivery reviews 2009-02, Vol.61 (2), p.140-157
Hauptverfasser: Csaba, Noemi, Garcia-Fuentes, Marcos, Alonso, Maria Jose
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 157
container_issue 2
container_start_page 140
container_title Advanced drug delivery reviews
container_volume 61
creator Csaba, Noemi
Garcia-Fuentes, Marcos
Alonso, Maria Jose
description The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.
doi_str_mv 10.1016/j.addr.2008.09.005
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66942723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X08002640</els_id><sourcerecordid>66942723</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</originalsourceid><addsrcrecordid>eNqFkM1KAzEYRYMotlZfwIUUBHczfvmbScCNFP-g6EbBXUgzXyBlOqnJtODbO6UFd7q6m3PP4hBySaGkQKvbZWmbJpUMQJWgSwB5RMZU1axQTItjMh4gXQjQnyNylvMSgLK6glMyopoyyiWMyfWr7eLapj64FvPUxzTtbLbtdGudC53tQ-zOyYm3bcaLw07Ix-PD--y5mL89vczu54XjSvaFpExqrxxDZTlfOM0F1cohyMpqUUtlgVPuhMWGVY0GTz0DYaWUFLwAzyfkZu9dp_i1wdybVcgO29Z2GDfZVJUWrGb8X5ABV4JXegDZHnQp5pzQm3UKK5u-DQWza2iWZtfQ7Boa0GZoOJyuDvbNYoXN7-UQbQDu9gAOMbYBk8kuYOewCQldb5oY_vL_AGy5gDs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20384369</pqid></control><display><type>article</type><title>Nanoparticles for nasal vaccination</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Csaba, Noemi ; Garcia-Fuentes, Marcos ; Alonso, Maria Jose</creator><creatorcontrib>Csaba, Noemi ; Garcia-Fuentes, Marcos ; Alonso, Maria Jose</creatorcontrib><description>The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.</description><identifier>ISSN: 0169-409X</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2008.09.005</identifier><identifier>PMID: 19121350</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Intranasal ; Animals ; Antigen delivery ; Bioadhesion ; Drug Carriers - administration &amp; dosage ; Drug Delivery Systems - methods ; Humans ; Mucosal immunity ; Nanoparticles ; Nanoparticles - administration &amp; dosage ; Nasal administration ; Nasal Mucosa - immunology ; Nasal Mucosa - metabolism ; Transmucosal transport ; Vaccines - administration &amp; dosage</subject><ispartof>Advanced drug delivery reviews, 2009-02, Vol.61 (2), p.140-157</ispartof><rights>2008 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</citedby><cites>FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.addr.2008.09.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19121350$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Csaba, Noemi</creatorcontrib><creatorcontrib>Garcia-Fuentes, Marcos</creatorcontrib><creatorcontrib>Alonso, Maria Jose</creatorcontrib><title>Nanoparticles for nasal vaccination</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.</description><subject>Administration, Intranasal</subject><subject>Animals</subject><subject>Antigen delivery</subject><subject>Bioadhesion</subject><subject>Drug Carriers - administration &amp; dosage</subject><subject>Drug Delivery Systems - methods</subject><subject>Humans</subject><subject>Mucosal immunity</subject><subject>Nanoparticles</subject><subject>Nanoparticles - administration &amp; dosage</subject><subject>Nasal administration</subject><subject>Nasal Mucosa - immunology</subject><subject>Nasal Mucosa - metabolism</subject><subject>Transmucosal transport</subject><subject>Vaccines - administration &amp; dosage</subject><issn>0169-409X</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1KAzEYRYMotlZfwIUUBHczfvmbScCNFP-g6EbBXUgzXyBlOqnJtODbO6UFd7q6m3PP4hBySaGkQKvbZWmbJpUMQJWgSwB5RMZU1axQTItjMh4gXQjQnyNylvMSgLK6glMyopoyyiWMyfWr7eLapj64FvPUxzTtbLbtdGudC53tQ-zOyYm3bcaLw07Ix-PD--y5mL89vczu54XjSvaFpExqrxxDZTlfOM0F1cohyMpqUUtlgVPuhMWGVY0GTz0DYaWUFLwAzyfkZu9dp_i1wdybVcgO29Z2GDfZVJUWrGb8X5ABV4JXegDZHnQp5pzQm3UKK5u-DQWza2iWZtfQ7Boa0GZoOJyuDvbNYoXN7-UQbQDu9gAOMbYBk8kuYOewCQldb5oY_vL_AGy5gDs</recordid><startdate>20090227</startdate><enddate>20090227</enddate><creator>Csaba, Noemi</creator><creator>Garcia-Fuentes, Marcos</creator><creator>Alonso, Maria Jose</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20090227</creationdate><title>Nanoparticles for nasal vaccination</title><author>Csaba, Noemi ; Garcia-Fuentes, Marcos ; Alonso, Maria Jose</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-51259f8c2e8a33bc934198ce056a94758a0313c4aed26d90f1f204a55510f40f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Intranasal</topic><topic>Animals</topic><topic>Antigen delivery</topic><topic>Bioadhesion</topic><topic>Drug Carriers - administration &amp; dosage</topic><topic>Drug Delivery Systems - methods</topic><topic>Humans</topic><topic>Mucosal immunity</topic><topic>Nanoparticles</topic><topic>Nanoparticles - administration &amp; dosage</topic><topic>Nasal administration</topic><topic>Nasal Mucosa - immunology</topic><topic>Nasal Mucosa - metabolism</topic><topic>Transmucosal transport</topic><topic>Vaccines - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Csaba, Noemi</creatorcontrib><creatorcontrib>Garcia-Fuentes, Marcos</creatorcontrib><creatorcontrib>Alonso, Maria Jose</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Csaba, Noemi</au><au>Garcia-Fuentes, Marcos</au><au>Alonso, Maria Jose</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanoparticles for nasal vaccination</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2009-02-27</date><risdate>2009</risdate><volume>61</volume><issue>2</issue><spage>140</spage><epage>157</epage><pages>140-157</pages><issn>0169-409X</issn><eissn>1872-8294</eissn><abstract>The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially attractive for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable way for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate delivery systems could also provide more effective antigen recognition by immune cells. These represent key factors in the optimal processing and presentation of the antigen, and therefore in the subsequent development of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising way for nasal mucosal vaccination.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>19121350</pmid><doi>10.1016/j.addr.2008.09.005</doi><tpages>18</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0169-409X
ispartof Advanced drug delivery reviews, 2009-02, Vol.61 (2), p.140-157
issn 0169-409X
1872-8294
language eng
recordid cdi_proquest_miscellaneous_66942723
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Administration, Intranasal
Animals
Antigen delivery
Bioadhesion
Drug Carriers - administration & dosage
Drug Delivery Systems - methods
Humans
Mucosal immunity
Nanoparticles
Nanoparticles - administration & dosage
Nasal administration
Nasal Mucosa - immunology
Nasal Mucosa - metabolism
Transmucosal transport
Vaccines - administration & dosage
title Nanoparticles for nasal vaccination
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A41%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanoparticles%20for%20nasal%20vaccination&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Csaba,%20Noemi&rft.date=2009-02-27&rft.volume=61&rft.issue=2&rft.spage=140&rft.epage=157&rft.pages=140-157&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2008.09.005&rft_dat=%3Cproquest_cross%3E66942723%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20384369&rft_id=info:pmid/19121350&rft_els_id=S0169409X08002640&rfr_iscdi=true